[
  {
    "ts": null,
    "headline": "Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Truist lowered its price objective on Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The firm maintained a Buy rating on the stock. In a note to clients, the analyst said the sharp pullback after […]",
    "url": "https://finnhub.io/api/news?id=360ccd446f42307e67d702a61f52d2d816568fc7270794526d23150cd6f5a0b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770469961,
      "headline": "Truist Cuts Boston Scientific Corporation (BSX) Price Target but Maintains Buy After Earnings Pullback",
      "id": 138384987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Truist lowered its price objective on Boston Scientific Corporation (NYSE:BSX) to $95 from $120. The firm maintained a Buy rating on the stock. In a note to clients, the analyst said the sharp pullback after […]",
      "url": "https://finnhub.io/api/news?id=360ccd446f42307e67d702a61f52d2d816568fc7270794526d23150cd6f5a0b9"
    }
  },
  {
    "ts": null,
    "headline": "Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset",
    "summary": "The fair value estimate for Boston Scientific has been reset from US$125.45 to US$108.66, while the modeled discount rate is essentially steady at 7.87% and revenue growth expectations move from 11.18% to a more conservative 10.74%. This shift lines up with recent Street research, where many firms are trimming targets and treating earlier valuation levels as too rich, even as some still describe the stock as a preferred large cap MedTech name or a top idea alongside a select peer group. As...",
    "url": "https://finnhub.io/api/news?id=77ef37a78150dd56200d5e5bf7a32d5ad3ad4e059b2ca79821ed5b1afa1672bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770451562,
      "headline": "Why Analysts See Boston Scientific (BSX) Differently After Target Cuts And A Fair Value Reset",
      "id": 138383879,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The fair value estimate for Boston Scientific has been reset from US$125.45 to US$108.66, while the modeled discount rate is essentially steady at 7.87% and revenue growth expectations move from 11.18% to a more conservative 10.74%. This shift lines up with recent Street research, where many firms are trimming targets and treating earlier valuation levels as too rich, even as some still describe the stock as a preferred large cap MedTech name or a top idea alongside a select peer group. As...",
      "url": "https://finnhub.io/api/news?id=77ef37a78150dd56200d5e5bf7a32d5ad3ad4e059b2ca79821ed5b1afa1672bd"
    }
  }
]